KR0156587B1 - Composition for therapeutic agent against chronic viral hepatic disease - Google Patents
Composition for therapeutic agent against chronic viral hepatic diseaseInfo
- Publication number
- KR0156587B1 KR0156587B1 KR1019930701862A KR930701862A KR0156587B1 KR 0156587 B1 KR0156587 B1 KR 0156587B1 KR 1019930701862 A KR1019930701862 A KR 1019930701862A KR 930701862 A KR930701862 A KR 930701862A KR 0156587 B1 KR0156587 B1 KR 0156587B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- therapeutic agent
- chronic viral
- agent against
- hepatic disease
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 208000019423 liver disease Diseases 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010019799 Hepatitis viral Diseases 0.000 abstract 1
- 201000001862 viral hepatitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90124775A EP0491077A1 (en) | 1990-12-19 | 1990-12-19 | A composition used as a therapeutic agent against chronic viral hepatic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
KR0156587B1 true KR0156587B1 (en) | 1998-10-15 |
Family
ID=8204863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930701862A KR0156587B1 (en) | 1990-12-19 | 1993-06-18 | Composition for therapeutic agent against chronic viral hepatic disease |
Country Status (15)
Country | Link |
---|---|
US (2) | US6020167A (ko) |
EP (2) | EP0491077A1 (ko) |
JP (2) | JP3857305B2 (ko) |
KR (1) | KR0156587B1 (ko) |
AT (1) | ATE170220T1 (ko) |
AU (1) | AU657935B2 (ko) |
CA (1) | CA2098021C (ko) |
CZ (1) | CZ290233B6 (ko) |
DE (1) | DE69130071T3 (ko) |
DK (1) | DK0563093T4 (ko) |
ES (1) | ES2121000T5 (ko) |
HK (1) | HK1002901A1 (ko) |
HU (1) | HU216301B (ko) |
SK (1) | SK280551B6 (ko) |
WO (1) | WO1992011368A1 (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988010300A1 (en) * | 1987-06-22 | 1988-12-29 | Medico Labs Ag | Heterologous viral peptide particle immunogens |
EP0491077A1 (en) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
DE4107612A1 (de) * | 1991-03-09 | 1992-09-10 | Behringwerke Ag | Rekombinante proteine mit der immunreaktivitaet des hepatitis b virus e antigens (hbeag), verfahren zu ihrer herstellung und ihre verwendung in immunoassays und impfstoffen |
US6689363B1 (en) | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
US6509149B2 (en) * | 1995-06-06 | 2003-01-21 | Hybridon, Inc. | HPV-specific oligonucleotides |
BR9709993A (pt) * | 1996-06-25 | 1999-08-10 | Stichting Inst Dierhouderij | Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica |
US7091324B2 (en) | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
CN1268345C (zh) * | 2000-03-29 | 2006-08-09 | 乔治敦大学 | 治疗丁型肝炎病毒感染的核苷化合物 |
IL142802A (en) * | 2000-04-27 | 2015-01-29 | Enzo Therapeutics Inc | Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
KR20030074787A (ko) * | 2001-02-05 | 2003-09-19 | 스트레스젠 바이오테크놀러지스 코포레이션 | B형 간염 바이러스 치료 |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
US8420353B2 (en) * | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
DE10339927A1 (de) * | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
GB0326416D0 (en) | 2003-11-12 | 2003-12-17 | Karolinska Innovations Ab | Methods and means relating to hepatitis B infection |
WO2005050214A2 (en) * | 2003-11-12 | 2005-06-02 | Hbv Theranostica Ab | Methods and means relating to hepatitis b infection |
US9603921B2 (en) * | 2004-10-27 | 2017-03-28 | Janssen Vaccines Ag | Virosome particles comprising antigens from influenza virus and hepatitis b virus |
US8071561B2 (en) * | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
WO2009092396A1 (en) | 2008-01-25 | 2009-07-30 | Universitätsklinikum Heidelberg | Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
CN101485672B (zh) * | 2008-12-05 | 2010-08-25 | 广东粤龙药业有限公司 | 异丙景糖酐在制备治疗人HBeAg阳性慢性乙型肝炎药物中的应用 |
US10076570B2 (en) | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
EP2461826A2 (en) | 2009-08-07 | 2012-06-13 | Transgene SA | Composition for treating hbv infection |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US34705A (en) * | 1862-03-18 | Improvement in tompions for fire-arms | ||
US3636191A (en) * | 1969-10-08 | 1972-01-18 | Cancer Res Inst | Vaccine against viral hepatitis and process |
FR2480779B2 (fr) * | 1979-08-30 | 1986-07-18 | Anvar | Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur |
IN151589B (ko) * | 1978-12-22 | 1983-05-28 | Biogen Nv | |
EP0182442B2 (en) * | 1978-12-22 | 1996-04-03 | Biogen, Inc. | Recombinant DNA molecules and their method of production |
US4935235A (en) * | 1979-05-24 | 1990-06-19 | The Regents Of The University Of California | Non-passageable viruses |
IE52036B1 (en) * | 1979-05-24 | 1987-05-27 | Univ California | Non-passageable viruses |
US5196194A (en) * | 1979-05-24 | 1993-03-23 | The Regents Of The University Of California | Vaccines containing Hepatitis B S-protein |
USRE34705E (en) | 1979-08-30 | 1994-08-23 | Institut Pasteur | Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby |
US4415491A (en) * | 1980-01-14 | 1983-11-15 | The Regents Of The University Of California | Synthetic vaccine peptide epitomes of hepatitis B surface antigen |
EP0038765B1 (fr) * | 1980-04-22 | 1987-09-02 | Institut Pasteur | Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin |
FI83662C (fi) * | 1980-07-17 | 1991-08-12 | Scripps Clinic Res | Diagnostik antikropp och foerfarande foer dess framstaellning. |
GR76274B (ko) * | 1981-08-04 | 1984-08-04 | Univ California | |
AU8746582A (en) * | 1981-09-02 | 1983-03-10 | Biogen N.V. | Hepatitis b virus e type antigen |
US4741901A (en) * | 1981-12-03 | 1988-05-03 | Genentech, Inc. | Preparation of polypeptides in vertebrate cell culture |
JPS58194897A (ja) * | 1982-05-07 | 1983-11-12 | Takeda Chem Ind Ltd | 新規dna,その製造方法およびそれで形質転換させた宿主 |
JPS5936698A (ja) * | 1982-08-20 | 1984-02-28 | Science & Tech Agency | B型肝炎ウイルス遺伝子を組込んだ組換えdnaおよび形質転換動物細胞 |
US4977092A (en) * | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US5198348A (en) * | 1982-08-30 | 1993-03-30 | Amgen Inc. | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
JPS5974985A (ja) * | 1982-10-19 | 1984-04-27 | Takeda Chem Ind Ltd | 新規dna |
CA1341116C (en) * | 1983-02-22 | 2000-10-17 | Rae Lyn Burke | Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein |
US4696898A (en) * | 1984-01-16 | 1987-09-29 | Integrated Genetics, Inc. | Vector encoding hepatitis B surface antigen |
FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
FR2560890B1 (fr) * | 1984-03-07 | 1987-10-16 | Grp Genie Genetique | Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention |
US5158769A (en) * | 1984-03-07 | 1992-10-27 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US5324513A (en) * | 1984-03-07 | 1994-06-28 | Institut Pasteur | Composition useful for the fabrication of vaccines |
US5204096A (en) * | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US4861588A (en) * | 1985-02-05 | 1989-08-29 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US4847080A (en) * | 1984-03-07 | 1989-07-11 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers |
US4777240A (en) * | 1984-03-08 | 1988-10-11 | Scripps Clinic And Research Foundation | SV40 expression vector containing HBxAg as an expression marker |
US4942125A (en) * | 1984-09-07 | 1990-07-17 | Scripps Clinic And Research Foundation | SV40 expression vector containing HBxAg as an expression marker |
US4599230A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599231A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
AU579148B2 (en) * | 1984-03-09 | 1988-11-17 | Scripps Clinic And Research Foundation | Synthetic hepatitis b virus vaccine including both t cell and b cell determinants |
US5098704A (en) * | 1984-06-18 | 1992-03-24 | Chiron Corporation | Hepatitis surface antigen particle vaccine |
EP0171908A3 (en) * | 1984-07-11 | 1987-07-15 | Takeda Chemical Industries, Ltd. | Hepatitis b virus surface antigen and production thereof |
GB8421282D0 (en) * | 1984-08-22 | 1984-09-26 | Connaught Lab | Multispecific antigenic proteins |
US4722940A (en) * | 1984-08-23 | 1988-02-02 | Georgia Tech Research Corporation | Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions |
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
EP0175261B1 (en) * | 1984-09-12 | 1991-12-11 | Chiron Corporation | Hybrid particle immunogens |
US4639371A (en) * | 1984-10-02 | 1987-01-27 | New York Blood Center, Inc. | Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom |
EP0180012A1 (de) * | 1984-10-27 | 1986-05-07 | Wolfram H. Prof. Dr. Gerlich | Immunogene Polypeptidsequenz des Hepatitis B-Virus |
US4683136A (en) * | 1985-03-06 | 1987-07-28 | Scripps Clinic And Research Foundation | Proteinaceous antigens with conformation-independent and conformation-dependent determinants |
CA1324094C (en) * | 1985-04-03 | 1993-11-09 | Dino Dina | Hepatitis a virus vaccines |
FI861417A0 (fi) * | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US5837249A (en) * | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
US4639271A (en) * | 1985-04-24 | 1987-01-27 | Moore Business Forms, Inc. | Chromogenic mixtures |
FR2581394B1 (fr) * | 1985-05-02 | 1988-08-05 | Grp Genie Genetique | Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes |
US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
JPH084507B2 (ja) * | 1985-10-03 | 1996-01-24 | 武田薬品工業株式会社 | 新規dnaおよびポリペプチド |
US4959323A (en) * | 1985-11-04 | 1990-09-25 | Mt. Sinai School Of Medicine Of The City University Of New York | Production and use of pre S polypeptides of hepatitis B virus |
US4895800A (en) * | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
US4816564A (en) * | 1986-01-31 | 1989-03-28 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
US4742158A (en) * | 1986-04-25 | 1988-05-03 | Merck & Co., Inc. | Purification of hepatitis pre-S antigens by polymerized serum albumin affinity binding |
IE59389B1 (en) * | 1986-05-23 | 1994-12-23 | Merck & Co Inc | Method for producing hepatitis b virus core antigen (HBcAg) in yeast |
CA1310602C (en) * | 1986-06-03 | 1992-11-24 | Hajime Horii | Yeast promoter and process for preparing heterologous protein |
JPH01500515A (ja) * | 1986-06-20 | 1989-02-23 | スクリップス クリニック アンド リサーチ ファウンデーション | B型肝炎ウィルス表面抗原のプレs領域のt及びb細胞エピトープ |
US5068185A (en) * | 1986-07-10 | 1991-11-26 | Merck & Co., Inc. | Trains of yeast for the expression of heterologous genes |
IL79740A0 (en) * | 1986-08-17 | 1986-11-30 | Yeda Res & Dev | Hepatitis vaccine |
US4882145A (en) * | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4818527A (en) * | 1986-12-09 | 1989-04-04 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
ZA88488B (en) * | 1987-01-30 | 1988-10-26 | Smith Kline Rit | Hepatitis b virus surface antigens and hybrid antigens containing them |
EP1088830A3 (en) * | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Hepatitis b surface antigen particles |
WO1988010300A1 (en) * | 1987-06-22 | 1988-12-29 | Medico Labs Ag | Heterologous viral peptide particle immunogens |
US4883865A (en) * | 1987-09-30 | 1989-11-28 | Merck & Co. Inc. | Recovery of pres2+s antigen |
US4963483A (en) * | 1987-10-13 | 1990-10-16 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
US5011915A (en) * | 1987-10-26 | 1991-04-30 | Merck & Co., Inc. | Process for purifying recombinant hepatitis antigens |
US5039522A (en) * | 1988-01-29 | 1991-08-13 | New York Blood Center, Inc. | Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen |
NZ229260A (en) * | 1988-06-03 | 1994-02-25 | Merck & Co Inc | Hepatitis b virus, expression cassette for pre-s domain, host cells and |
US5242812A (en) * | 1989-02-07 | 1993-09-07 | Bio-Technology General Corp. | Method for production and purification of hepatitis B vaccine |
US5462863A (en) * | 1989-02-09 | 1995-10-31 | Development Center For Biotechnology | Isolation of Hepatitis B surface antigen from transformed yeast cells |
GB8903313D0 (en) * | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
DK0414374T3 (da) * | 1989-07-25 | 1998-03-09 | Smithkline Beecham Biolog | Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf |
EP0421626A1 (en) * | 1989-09-19 | 1991-04-10 | Merck & Co. Inc. | Vaccine for aids and hepatitis B |
EP0491077A1 (en) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
US5102989A (en) * | 1991-03-15 | 1992-04-07 | Merck & Co., Inc. | Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells |
IL101653A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Multiple hepatitis b virus surface proteins which form particles |
CA2067003A1 (en) * | 1991-04-29 | 1992-10-30 | Peter J. Kniskern | Hbsag escape mutant vaccine |
US5840303A (en) * | 1991-08-26 | 1998-11-24 | The Scripps Research Foundation | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
JP2501186Y2 (ja) * | 1992-03-31 | 1996-06-12 | 株式会社栗本鐵工所 | ハンマ―ミル |
CN1063343C (zh) * | 1993-04-27 | 2001-03-21 | 中国科学院上海生物化学研究所 | 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白 |
CN1094311A (zh) * | 1993-04-27 | 1994-11-02 | 中国科学院上海生物化学研究所 | 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白 |
CN1059927C (zh) * | 1994-03-10 | 2000-12-27 | 中国科学院上海生物化学研究所 | 羧端带有前表面抗原1抗原决定簇的乙肝表面抗原融合基因及其编码蛋白 |
US5792163A (en) * | 1996-01-03 | 1998-08-11 | Hitzig; Gary | Linear punch |
-
1990
- 1990-12-19 EP EP90124775A patent/EP0491077A1/en not_active Withdrawn
-
1991
- 1991-12-19 DK DK92900527T patent/DK0563093T4/da active
- 1991-12-19 ES ES92900527T patent/ES2121000T5/es not_active Expired - Lifetime
- 1991-12-19 DE DE69130071T patent/DE69130071T3/de not_active Expired - Lifetime
- 1991-12-19 CZ CZ19931186A patent/CZ290233B6/cs not_active IP Right Cessation
- 1991-12-19 WO PCT/EP1991/002460 patent/WO1992011368A1/en active IP Right Grant
- 1991-12-19 SK SK636-93A patent/SK280551B6/sk unknown
- 1991-12-19 AU AU90817/91A patent/AU657935B2/en not_active Ceased
- 1991-12-19 JP JP50100592A patent/JP3857305B2/ja not_active Expired - Lifetime
- 1991-12-19 HU HU9301794A patent/HU216301B/hu unknown
- 1991-12-19 CA CA002098021A patent/CA2098021C/en not_active Expired - Lifetime
- 1991-12-19 US US08/075,520 patent/US6020167A/en not_active Expired - Lifetime
- 1991-12-19 AT AT92900527T patent/ATE170220T1/de not_active IP Right Cessation
- 1991-12-19 EP EP92900527A patent/EP0563093B2/en not_active Expired - Lifetime
-
1993
- 1993-06-18 KR KR1019930701862A patent/KR0156587B1/ko not_active IP Right Cessation
-
1998
- 1998-03-10 HK HK98101997A patent/HK1002901A1/xx not_active IP Right Cessation
-
2000
- 2000-06-07 JP JP2000175584A patent/JP2001019643A/ja active Pending
-
2003
- 2003-03-21 US US10/394,896 patent/US20030235591A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SK63693A3 (en) | 1993-10-06 |
DE69130071T2 (de) | 1999-01-07 |
DE69130071D1 (de) | 1998-10-01 |
WO1992011368A1 (en) | 1992-07-09 |
AU657935B2 (en) | 1995-03-30 |
CA2098021C (en) | 2000-04-25 |
HUT66437A (en) | 1994-11-28 |
US20030235591A1 (en) | 2003-12-25 |
DK0563093T4 (da) | 2008-01-21 |
CZ118693A3 (en) | 1994-02-16 |
DK0563093T3 (da) | 1999-02-08 |
EP0563093B2 (en) | 2007-10-03 |
HU9301794D0 (en) | 1993-10-28 |
EP0491077A1 (en) | 1992-06-24 |
SK280551B6 (sk) | 2000-03-13 |
CA2098021A1 (en) | 1992-06-20 |
JP2001019643A (ja) | 2001-01-23 |
US6020167A (en) | 2000-02-01 |
HU216301B (hu) | 1999-06-28 |
HK1002901A1 (en) | 1998-09-25 |
EP0563093A1 (en) | 1993-10-06 |
JPH06507303A (ja) | 1994-08-25 |
AU9081791A (en) | 1992-07-22 |
JP3857305B2 (ja) | 2006-12-13 |
EP0563093B1 (en) | 1998-08-26 |
DE69130071T3 (de) | 2008-02-21 |
ATE170220T1 (de) | 1998-09-15 |
CZ290233B6 (cs) | 2002-06-12 |
ES2121000T5 (es) | 2008-04-16 |
ES2121000T3 (es) | 1998-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0156587B1 (en) | Composition for therapeutic agent against chronic viral hepatic disease | |
PT725824E (pt) | Epitopos de celulas t humanas imunodominantes do virus da hepatite c | |
TW249226B (ko) | ||
EP0435443A3 (en) | Use of 15-keto-prostaglandin compound for improvement of encephalic function | |
HK55896A (en) | Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2' 3'-didehydrothymidine) in treating patients infected with retrovirus | |
KR910019620A (ko) | 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료 | |
GR3018674T3 (en) | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds | |
USD281353S (en) | Collimator for dental x-ray instrument aiming rings | |
AP9400647A0 (en) | Medicaments for use in treatment of HIV or cancer patients. | |
GR3026105T3 (en) | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds | |
EP0430552A3 (en) | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds | |
ATE196631T1 (de) | Xamonelin-tartrat | |
CS318690A3 (en) | Pharmaceutical composition usable for depression therapy | |
AU2715288A (en) | Human respiratory syncytialvirus vaccine derived from the 1a (9.5 kd) protein | |
EP0362755A3 (en) | Human cytotoxic t-cell clone and antibody thereto | |
IT1217837B (it) | Procedimento per la preparazione del "alfa /4(1,1 dimetiletil)fenil/piperidinbutanolo" | |
EP0505608A3 (en) | Alpha-dihydroergocryptine pharmaceutical preparations with neuroprotective acitivity | |
HU905997D0 (en) | Process for the preparation of (1r,2s)-(-)-2-(2'-dimethyl-amino-etoxi)-1.7.7- -trimethyl-bicyclo(2.2.1)heptane | |
IT9003745A0 (it) | Ago a farfalla di sicurezza per uso medicale. | |
ATE64855T1 (de) | Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom. | |
ATE72948T1 (de) | Schutzmaske fuer medizinische zwecke, insbesondere fuer chirurgen. | |
ZA913160B (en) | Cytotoxic bicyclo(7.3.1)tridec-4-ene-2,6-diyne compounds and process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20030707 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |